TP53 and mantle cell lymphoma: We, therefore, hypothesized that GSK2830371 could potentiate the anti-lymphoma effects of p53 inducers in MCL cells and confirmed this hypothesis using combination studies in which cells were treated with GSK2830371 and the MDM2 inhibitor Nutlin-3a, the proteasome inhibitor bortezomib, and the anthracycline doxorubicin.